• Mutation; HGNC; HGNC:11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line).
  

PubMed=20687223; DOI=10.1002/pros.21185
Kojima K., Fujita Y., Nozawa Y., Deguchi T., Ito M.
MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms.
Prostate 70:1501-1512(2010)

PubMed=23876400; DOI=10.1016/j.cyto.2013.06.313
Kato T., Fujita Y., Nakane K., Mizutani K., Terazawa R., Ehara H., Kanimoto Y., Kojima T., Nozawa Y., Deguchi T., Ito M.
CCR1/CCL5 interaction promotes invasion of taxane-resistant PC3 prostate cancer cells by increasing secretion of MMPs 2/9 and by activating ERK and Rac signaling.
Cytokine 64:251-257(2013)

PubMed=27687545; DOI=10.1016/j.bbrc.2016.09.128
Sobue S., Mizutani N., Aoyama Y., Kawamoto Y., Suzuki M., Nozawa Y., Ichihara M., Murate T.
Mechanism of paclitaxel resistance in a human prostate cancer cell line, PC3-PR, and its sensitization by cabazitaxel.
Biochem. Biophys. Res. Commun. 479:808-813(2016)